Why Did ReShape Lifesciences Plunge 11.11% on Public Offering News?

On April 11, 2025, ReShape Lifesciences experienced a significant drop of 11.11% in pre-market trading, sparking concerns among investors about the company's recent financial moves.

ReShape Lifesciences has announced a public offering priced at $2.33 per unit, aiming to raise approximately $6 million. This offering includes common shares and warrants, with the warrants set to become exercisable pending shareholder approval. The offering is expected to close by February 18, 2025.

Analysts have provided mixed sentiments regarding the company's future performance. One analyst has set a one-year price target of $1.00 for ReShape Lifesciences, indicating a potential upside of 192.23% from the current market value. However, the consensus recommendation from one brokerage firm is a "Hold" rating, suggesting caution among investors.